Nektar Therapeutics, a San Carlos, California-based drug delivery developer, said Monday it plans to acquire Aerogen in a deal worth about $32 million, including $8 million in cash and $24 million in stock.The deal is expected to close during the fourth quarter.
- read this story from MarketWatch for more